Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) Operating Expenses (2022 - 2025)

Gossamer Bio's Operating Expenses history spans 4 years, with the latest figure at $59.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 31.49% year-over-year to $59.8 million; the TTM value through Dec 2025 reached $219.2 million, up 25.53%, while the annual FY2025 figure was $219.2 million, 25.53% up from the prior year.
  • Operating Expenses reached $59.8 million in Q4 2025 per GOSS's latest filing, down from $62.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $62.4 million in Q3 2025 to a low of $40.5 million in Q3 2023.
  • Average Operating Expenses over 4 years is $49.8 million, with a median of $48.5 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: decreased 27.72% in 2023, then surged 43.8% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $54.4 million in 2022, then dropped by 9.81% to $49.0 million in 2023, then fell by 7.18% to $45.5 million in 2024, then soared by 31.49% to $59.8 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Operating Expenses are $59.8 million (Q4 2025), $62.4 million (Q3 2025), and $50.3 million (Q2 2025).